Literature DB >> 17157012

Quantitative structure-activity relationship (QSAR) of indoloacetamides as inhibitors of human isoprenylcysteine carboxyl methyltransferase.

Jo-Lene Leow1, Rudi Baron, Patrick J Casey, Mei-Lin Go.   

Abstract

A QSAR is developed for the isoprenylcysteine carboxyl methyltransferase (ICMT) inhibitory activities of a series of indoloacetamides (n=72) that are structurally related to cysmethynil, a selective ICMT inhibitor. Multivariate analytical tools (principal component analysis (PCA) and projection to latent structures (PLS)), multi-linear regression (MLR) and comparative molecular field analysis (CoMFA) are used to develop a suitably predictive model for the purpose of optimizing and identifying members with more potent inhibitory activity. The resulting model shows that good activity is determined largely by the characteristics of the substituent attached to the indole nitrogen, which should be a lipophilic residue with fairly wide dimensions. In contrast, the substituted phenyl ring attached to the indole ring must be of limited dimensions and lipophilicity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17157012      PMCID: PMC1941685          DOI: 10.1016/j.bmcl.2006.11.030

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  19 in total

Review 1.  Farnesyltransferase inhibitors as anticancer agents: critical crossroads.

Authors:  Ronald J Doll; Paul Kirschmeier; W Robert Bishop
Journal:  Curr Opin Drug Discov Devel       Date:  2004-07

2.  Prenylated protein methyltransferases do not distinguish between farnesylated and geranylgeranylated substrates.

Authors:  D Pérez-Sala; B A Gilbert; E W Tan; R R Rando
Journal:  Biochem J       Date:  1992-06-15       Impact factor: 3.857

3.  Kinetic mechanism of isoprenylated protein methyltransferase.

Authors:  Y Q Shi; R R Rando
Journal:  J Biol Chem       Date:  1992-05-15       Impact factor: 5.157

4.  Amide-substituted farnesylcysteine analogs as inhibitors of human isoprenylcysteine carboxyl methyltransferase.

Authors:  James L Donelson; Heather B Hodges; Daniel D Macdougall; Brian S Henriksen; Christine A Hrycyna; Richard A Gibbs
Journal:  Bioorg Med Chem Lett       Date:  2006-06-13       Impact factor: 2.823

Review 5.  Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic.

Authors:  J B Gibbs; A Oliff; N E Kohl
Journal:  Cell       Date:  1994-04-22       Impact factor: 41.582

6.  Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes.

Authors:  J A Glomset; C C Farnsworth
Journal:  Annu Rev Cell Biol       Date:  1994

7.  Targeting Ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate.

Authors:  Ann M Winter-Vann; Barton A Kamen; Martin O Bergo; Stephen G Young; Stepan Melnyk; S Jill James; Patrick J Casey
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-15       Impact factor: 11.205

8.  Posttranslational modification of the Ha-ras oncogene protein: evidence for a third class of protein carboxyl methyltransferases.

Authors:  S Clarke; J P Vogel; R J Deschenes; J Stock
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

9.  Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice.

Authors:  N E Kohl; C A Omer; M W Conner; N J Anthony; J P Davide; S J deSolms; E A Giuliani; R P Gomez; S L Graham; K Hamilton
Journal:  Nat Med       Date:  1995-08       Impact factor: 53.440

Review 10.  Prenyl-binding domains: potential targets for Ras inhibitors and anti-cancer drugs.

Authors:  Yoel Kloog; Adrienne D Cox
Journal:  Semin Cancer Biol       Date:  2004-08       Impact factor: 15.707

View more
  1 in total

Review 1.  Small change, big effect: Taking RAS by the tail through suppression of post-prenylation carboxylmethylation.

Authors:  Hiu Yeung Lau; Mei Wang
Journal:  Small GTPases       Date:  2018-01-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.